Evidence map›Paper›PMID 34995708›Full record

ArticleFood and chemical toxicology : an international journal published for the British Industrial Biological Research Association2022

Withaferin A alleviates ethanol-induced liver injury by inhibiting hepatic lipogenesis.

Keisuke Hamada, Ping Wang, Yangliu Xia, Nana Yan, Shogo Takahashi, Kristopher W Krausz, Haiping Hao, Tingting Yan, Frank J Gonzalez

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.3field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Extraction of Oil fromFoods (Basel, Switzerland) · 2025
    Article
  5. Review
  6. Article
  7. Withaferin A in the Treatment of Liver Diseases: Progress and Pharmacokinetic Insights.Drug metabolism and disposition: the biological fate of chemicals · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Keisuke HamadaLaboratory of Metabolism, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA; Laboratory of Clinical Biochemistry, Tokyo University of Pharmacy and Life Sciences, Hachioji, Tokyo, 192-0392, Japan.
Ping WangLaboratory of Metabolism, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA; Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.
Yangliu XiaLaboratory of Metabolism, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA; School of Life Science and Medicine, Dalian University of Technology, Panjin, 124221, China.
Nana YanLaboratory of Metabolism, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA; State Key Laboratory of Natural Medicines, Key Laboratory of Drug Metabolism and Pharmacokinetics, China Pharmaceutical University, Nanjing, 210009, China.
Shogo TakahashiLaboratory of Metabolism, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA.
Kristopher W KrauszLaboratory of Metabolism, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA.
Haiping HaoState Key Laboratory of Natural Medicines, Key Laboratory of Drug Metabolism and Pharmacokinetics, China Pharmaceutical University, Nanjing, 210009, China.
Tingting YanLaboratory of Metabolism, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA. Electronic address: tingting.yan@nih.gov.
Frank J GonzalezLaboratory of Metabolism, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA. Electronic address: gonzalef@mail.nih.gov.
National Institutes of Health · USChina Pharmaceutical University · CNNational Cancer Institute · USShanghai Cancer Institute · CN

Funding

Xenobiotic metabolism, cancer chemoprevention and cancer biomarkersZIABC005708 · DIVISION OF BASIC SCIENCES - NCI · 2025 to 2025
$652k
Intramural NIH HHS ZIA BC005708
6 · The paper itself

Abstract

Withaferin A (WA) is a natural steroidal compound with reported hepatoprotective activities against various liver diseases. Whether WA has therapeutic effects on alcoholic liver disease has not been explored. A binge alcoholic liver injury model was employed by feeding C57BL/6J mice an ethanol (EtOH) diet for 10 days followed by an acute dose of EtOH to mimic clinical acute-upon-chronic liver injury. In this binge model, WA significantly reduced the binge EtOH-induced increase of serum aminotransaminase levels and decreased hepatic lipid accumulation. Mechanistically, WA decreased levels of hepatic lipogenesis gene mRNAs in vivo, including Srebp1c, Fasn, Acc1 and Fabp1. In EtOH-treated primary hepatocytes in vitro, WA decreased lipid accumulation by lowering the expression of the lipogenesis gene mRNAs Fasn and Acc1 as well as decreasing hepatocyte death. In the established binge alcoholic liver injury model, WA therapeutically reduced the EtOH-induced increase of serum aminotransaminase levels as well as hepatic lipid accumulation. These results demonstrate that WA reduces EtOH-induced liver injury by inhibiting hepatic lipogenesis, suggesting a potential therapeutic option for treating alcoholic liver injury.

Indexed as

Acetyl-CoA CarboxylaseAnimalsCell DeathEthanolFatty Acid Synthase, Type IFemaleHepatocytesHumansLipid MetabolismLipogenesisLiverLiver Diseases, AlcoholicMaleMiceMice, Inbred C57BLSterol Regulatory Element Binding Protein 1ACC1 protein, mouseAcetyl-CoA CarboxylaseEthanolFasn protein, mouseFatty Acid Synthase, Type ISrebf1 protein, mouseSterol Regulatory Element Binding Protein 1withaferin AWithanolidesAlcohol liver injuryBinge EtOH modelLipogenesisWithaferin A

Identifiers

PMID34995708
PMCPMC10353774
OpenAlexW4205844420

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.